#USA #Boston #biotechnology #Ginkgo Bioworks #cell programming

Ginkgo Bioworks Q1 2025 Financial Update

On May 6, 2025, Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) made a significant announcement regarding its financial results for the first quarter that ended March 31, 2025. Known for its innovative work in cell programming and biosecurity, Ginkgo continues to build its reputation as a leading platform in the biotechnology sector.

Financial Highlights

Ginkgo Bioworks reported total revenues of $48 million for Q1 2025, a 27% increase from $38 million in the same period in the previous year. This notable revenue growth was bolstered by a $7 million non-cash revenue from the termination of a customer agreement, while the actual total revenue, excluding this impact, stood at $41 million, marking a 8% increase year-over-year.

Revenue Breakdown

• - Cell Engineering Revenue: $31 million, reflecting a 10% growth compared to $28 million in Q1 2024. This increase is largely attributed to strengthening relationships with biopharma and government clients.
• - Biosecurity Revenue: Held steady at $10 million, consistent with the previous year's figures, evidencing stability in this vital segment.

Despite these encouraging figures, the net loss for Ginkgo Bioworks stood at $91 million, an improvement from a loss of $166 million during the same quarter in 2024. Furthermore, the company reported an adjusted EBITDA loss of $47 million, an improvement from $117 million in the prior year.

Cost-Reduction Initiatives

Ginkgo has made notable strides in its restructuring efforts, achieving an annualized run-rate cost reduction of $205 million as of Q1 2025, with a goal set to reach $250 million in savings by the end of the third quarter of 2025. Jason Kelly, co-founder and CEO, emphasized the importance of these restructuring measures, stating, “We're starting the year on a solid base thanks to the significant restructuring efforts of the past year.”

Strategic Updates

In addition to financial outcomes, Ginkgo Bioworks outlined its recent strategic positioning. The company continues to be recognized as a trusted R&D service provider to the U.S. government and the biopharma industry, with 28 ongoing government projects across Cell Engineering and Biosecurity and approximately $180 million in contracted backlog.

Innovation Initiatives

Ginkgo is also expanding its capabilities in data analytics and automation tools. Recent advancements include the publication of the GDPa1 antibody developability dataset, which could potentially drive future collaborations.

Moreover, Ginkgo’s automation division signed a contract with Aura Genetics, marking its entry into the diagnostics sector, signifying the company's ambition to diversify its offerings.

Financial Guidance for 2025

Ginkgo has revised its financial outlook for 2025. The updated guidance reflects a total revenue projection of $167 million to $187 million, with Cell Engineering revenue expected to be between $117 million and $137 million. Biosecurity revenue remains forecasted at a minimum of $50 million.

Upcoming Conference Call

Investors and stakeholders can participate in a videoconference today at 5:30 p.m. ET for an in-depth discussion regarding the Q1 results, recent updates, and Ginkgo's operational outlook. Questions can be submitted through social media or email prior to the presentation.

About Ginkgo Bioworks

Ginkgo Bioworks stands at the forefront of synthetic biology, providing a horizontal platform for cell programming that serves diverse markets, ranging from agriculture and food to pharmaceuticals and specialty chemicals. Its biosecurity initiatives aim to equip global leaders with the necessary infrastructure and technology to address biological threats.

For more updates and detailed information on future developments, visit Ginkgo's investor relations website and follow the company on social media channels.